GSGiulia Spoletini

Giulia Spoletini

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Giulia Spoletini has a total of 95 co-authors. Here are the top co-authors by number of shared publications:

  • Christine Etherington

    Leeds Regional Adult CF Centre, Department of Respiratory Medicine, Leeds Teaching Hospital NHS Trust, Leeds, UK

    9 shared publications
  • Daniel Peckham

    Leeds Institute of Medical Research, University of Leeds, Leeds, UK

    8 shared publications
  • Nicholas S. Hill

    Division of Pulmonary, Critical Care, and Sleep Medicine, Tufts Medical Center, Boston, MA, USA

    7 shared publications
  • Ian J. Clifton

    Department of Respiratory Medicine, Leeds Teaching Hospitals NHS Trust, Leeds, UK

    6 shared publications
  • Ian Clifton

    The Leeds Regional Adult Cystic Fibrosis Centre, St James's University Hospital, Leeds Teaching Hospital NHS Trust, Leeds, UK

    5 shared publications
  • Kim Pollard

    The Leeds Regional Adult Cystic Fibrosis Centre, St James's University Hospital, Leeds Teaching Hospital NHS Trust, Leeds, United Kingdom; Department of Physiotherapy, Leeds Teaching Hospital NHS Trust, Leeds, United Kingdom

    5 shared publications

Latest Publications

  • Open Access

    Providing Mobile Patient Access to Their Electronic Secondary Care Patient Record in Adults With Cystic Fibrosis: Results of a Prospective, Parallel, Randomized Open-Pilot Quantitative Study

    by Helen K Chadwick, Akhil Sawant, Helen White, Lindsey Gillgrass, Giulia Spoletini, Ian J Clifton, Christine Etherington, Daniel G Peckham

    Background: The Leeds regional adult and pediatric cystic fibrosis (CF) services introduced a modified primary care electronic health care record (EHR) in 2007. This resulted in a dramatic improvement in efficiency while providing the benefits of primary care developments, including full Patient Access to their records. Objective: This study aims to evaluate the feasibility, benefits, usability, and acceptability to patients of providing secure access to linked secondary care in CF. Methods: A prospective, parallel, randomized, open, pilot study with an intervention (EHR access; I) and a control group (no EHR access; C). People with CF were recruited on a consecutive basis, from outpatient clinics or as inpatients on the regional Leeds adult CF unit. At baseline and 6 months, paper-based self-report questionnaires were completed by participants to assess having access to EHR on psychological impact, patient satisfaction, quality of life (QoL), patient and physician relationships, and patterns and rates of adherence to treatment. Perceptions and engagement with Patient Access and computer literacy were also assessed. Once completed, participants were randomized into either the intervention or control group (1:1), with those in the intervention group given instructions about how to gain access and the functions of Patient Access by the research team. Results: A total of 91 people with CF completed the 6-month study (intervention n=45; median age 27.5, IQR 12.0 years; 22 male participants; control group n=46; median age 27.0, IQR 15.0 years; 29 male participants). Median number of logins was 9 (range 1-205). There was no effect of Patient Access on levels of anxiety (Generalized Anxiety Disorder-7; I=3.0, C=5.0), all symptom QoL scales and seven QoL domains (Cystic Fibrosis Questionnaire-Revised; respiratory I=63.89, C=55.56; weight I=100.00, C=66.67; digestion I=88.89, C=88.89; physical I=60.42, C=50.00; vitality I=54.17, C=41.67; emotional I=86.67, C=66.67; role I=75.0, C=75.0; body image I=77.78, C=66.67; eating disturbances I=88.89, C=100.0; treatment burden I=55.56, C=55.56), levels of depression (Patient Health Questionnaire-9; I=3.0, C=7.0), confidence in managing health care (Patient Activation Measure-13; I=66.67, C=60.63), level of trust in health care professionals (patient and provider perceived efficacy in patient-physician interaction; I=49.0, C=47.0), and computer literacy. Patient Access scored 86% for satisfaction, 82% for ease of use, and 80% for usefulness (Perceived Health Web Site Usability Questionnaire). Of those who had EHR access, 41 of 42 (98%) participants agreed that access to EHR should continue. Conclusions: This pilot study suggests that providing access to EHR in adults with CF does not appear to have a negative effect (increase levels of anxiety or decrease QoL), and uptake by patients has been very positive. Prospective studies are needed to investigate the long-term effect on objective health outcomes and how we can improve the functionality of such apps from the patient perspective. Trial Registration: ClinicalTrials.gov NCT06122025; https://clinicaltrials.gov/study/NCT06122025

  • Open Access

    Primary ciliary dyskinesia: a national expert consensus statement on standards of care

    by Evie A. Robson, Giulia Spoletini, Amelia Bercusson, Siobhan B. Carr, Mary Carroll, Katie Dexter, Lucy Dixon, Claire Hogg, Andrew Jones, Priti Kenia, et al.

    Primary ciliary dyskinesia (PCD) is a genetically and clinically diverse disorder characterised by loss of normal ciliary function leading to chronic oto-sino pulmonary disease, situs abnormalities and subfertility in men and women. There is limited evidence to support robust guidelines on the management of children and adults with PCD; however, there is a clear clinical need to establish a framework of care for the follow-up of these patients. The European Respiratory Society (ERS) has published consensus statements on diagnostic and treatment approaches in children with PCD, and the BEAT-PCD (Better Experimental Approaches to Treat PCD) network provides guidance on infection prevention and control. This is a national consensus statement to outline a set of standards for the provision of specialist care for children and adults with PCD living in England. A national PCD expert panel made up of specialists working in both paediatric and adult UK highly specialist management services, was established to create a consensus statement on the minimum standards of care for PCD. Using a modified Delphi process, consensus to a statement required at least 80% agreement within the PCD expert panel group. Patient organisation representatives were involved in reviewing the statement and have produced an accompanying layperson summary. We present a consensus statement on 15 standards covering provision of pulmonary, ear, nose and throat, and fertility care, screening for situs abnormalities and transition from paediatric to adult care services. It is targeted at clinicians and allied health professionals managing paediatric and adult patients with PCD, patient organisations and patients and their families.


  • Open Access

    Pneumonia and parapneumonic pleural effusions in adults with cystic fibrosis

    by Giulia Spoletini, Hisham Saumtaully, Akhil P. Sawant, Christine Etherington, Ian J. Clifton, Miles Denton, Daniel G. Peckham

    Cystic fibrosis (CF) is caused by an absence or dysfunction of the transmembrane conductance regulator (CFTR) protein, an anion channel exchanging chloride and bicarbonate across epithelia. In the airways, this ionic imbalance results in dehydrated airway surface liquid, tenacious secretions and impaired mucociliary clearance, leading to endobronchial infections, inflammation and progressive lung damage [1].


  • Open Access

    Providing Mobile Patient Access to Their Electronic Secondary Care Patient Record in Adults With Cystic Fibrosis: Results of a Prospective, Parallel, Randomized Open-Pilot Quantitative Study (Preprint)

    by Helen K Chadwick, Akhil Sawant, Helen White, Lindsey Gillgrass, Giulia Spoletini, Ian J Clifton, Christine Etherington, Daniel G Peckham

    BACKGROUND The Leeds regional adult and pediatric cystic fibrosis (CF) services introduced a modified primary care electronic health care record (EHR) in 2007. This resulted in a dramatic improvement in efficiency while providing the benefits of primary care developments, including full Patient Access to their records. OBJECTIVE This study aims to evaluate the feasibility, benefits, usability, and acceptability to patients of providing secure access to linked secondary care in CF. METHODS A prospective, parallel, randomized, open, pilot study with an intervention (EHR access; I) and a control group (no EHR access; C). People with CF were recruited on a consecutive basis, from outpatient clinics or as inpatients on the regional Leeds adult CF unit. At baseline and 6 months, paper-based self-report questionnaires were completed by participants to assess having access to EHR on psychological impact, patient satisfaction, quality of life (QoL), patient and physician relationships, and patterns and rates of adherence to treatment. Perceptions and engagement with Patient Access and computer literacy were also assessed. Once completed, participants were randomized into either the intervention or control group (1:1), with those in the intervention group given instructions about how to gain access and the functions of Patient Access by the research team. RESULTS A total of 91 people with CF completed the 6-month study (intervention n=45; median age 27.5, IQR 12.0 years; 22 male participants; control group n=46; median age 27.0, IQR 15.0 years; 29 male participants). Median number of logins was 9 (range 1-205). There was no effect of Patient Access on levels of anxiety (Generalized Anxiety Disorder-7; I=3.0, C=5.0), all symptom QoL scales and seven QoL domains (Cystic Fibrosis Questionnaire-Revised; respiratory I=63.89, C=55.56; weight I=100.00, C=66.67; digestion I=88.89, C=88.89; physical I=60.42, C=50.00; vitality I=54.17, C=41.67; emotional I=86.67, C=66.67; role I=75.0, C=75.0; body image I=77.78, C=66.67; eating disturbances I=88.89, C=100.0; treatment burden I=55.56, C=55.56), levels of depression (Patient Health Questionnaire-9; I=3.0, C=7.0), confidence in managing health care (Patient Activation Measure-13; I=66.67, C=60.63), level of trust in health care professionals (patient and provider perceived efficacy in patient-physician interaction; I=49.0, C=47.0), and computer literacy. Patient Access scored 86% for satisfaction, 82% for ease of use, and 80% for usefulness (Perceived Health Web Site Usability Questionnaire). Of those who had EHR access, 41 of 42 (98%) participants agreed that access to EHR should continue. CONCLUSIONS This pilot study suggests that providing access to EHR in adults with CF does not appear to have a negative effect (increase levels of anxiety or decrease QoL), and uptake by patients has been very positive. Prospective studies are needed to investigate the long-term effect on objective health outcomes and how we can improve the functionality of such apps from the patient perspective. CLINICALTRIAL ClinicalTrials.gov NCT06122025; https://clinicaltrials.gov/study/NCT06122025

  • Open Access

    Isolation ofBurkholderia cepaciacomplex in adults with primary ciliary dyskinesia

    by Giulia Spoletini, Connie Webster, Nicola Burke, Emma Farrell, Evie Robson, Miles Denton, Daniel Peckham

    The Burkholderia cepacia complex (BCC) is a group of Gram-negative opportunistic pathogens, encompassing 22 distinct species, characterised by inherent broad-spectrum antibiotic resistance [1]. BCC is widely recognised for its propensity to colonise the airways of individuals with cystic fibrosis (CF) and can cause acute infections among people with granulomatous diseases or immunodeficiency, and in those in intensive care or on mechanical ventilation [2–4].


  • Open Access

    Anti-inflammatory effects of elexacaftor/tezacaftor/ivacaftor in adults with cystic fibrosis heterozygous for F508del

    by Heledd H. Jarosz-Griffiths, Lindsey Gillgrass, Laura R. Caley, Giulia Spoletini, Ian J. Clifton, Christine Etherington, Sinisa Savic, Michael F. McDermott, Daniel Peckham

    Inflammation is a key driver in the pathogenesis of cystic fibrosis (CF). We assessed the effectiveness of elexacaftor/tezacaftor/ivacaftor (ETI) therapy on downregulating systemic and immune cell-derived inflammatory cytokines. We also monitored the impact of ETI therapy on clinical outcome. Adults with CF, heterozygous for F508del (n = 19), were assessed at baseline, one month and three months following ETI therapy, and clinical outcomes were measured, including sweat chloride, lung function, weight, neutrophil count and C-reactive protein (CRP). Cytokine quantifications were measured in serum and following stimulation of peripheral blood mononuclear cells (PBMCs) with lipopolysaccharide (LPS) and adenosine triphosphate and analysed using LEGEND plex™ Human Inflammation Panel 1 by flow cytometry (n = 19). ASC specks were measured in serum and caspase-1 activity and mRNA levels determined from stimulated PBMCs were determined. Patients remained stable over the study period. ETI therapy resulted in decreased sweat chloride concentrations (p < 0.0001), CRP (p = 0.0112) and neutrophil count (p = 0.0216) and increased percent predicted forced expiratory volume (ppFEV1) (p = 0.0399) from baseline to three months, alongside a trend increase in weight. Three months of ETI significantly decreased IL-18 (p< 0.0011, p < 0.0001), IL-1β (p<0.0013, p = 0.0476), IL-6 (p = 0.0109, p = 0.0216) and TNF (p = 0.0028, p = 0.0033) levels in CF serum and following PBMCs stimulation respectively. The corresponding mRNA levels were also found to be reduced in stimulated PBMCs, as well as reduced ASC specks and caspase-1 levels, indicative of NLRP3-mediated production of pro-inflammatory cytokines, IL-1β and IL-18. While ETI therapy is highly effective at reducing sweat chloride and improving lung function, it also displays potent anti-inflammatory properties, which are likely to contribute to improved long-term clinical outcomes.


  • Open Access

    Urinary bicarbonate and metabolic alkalosis during exacerbations in cystic fibrosis

    by Giulia Spoletini, Giles Fitch, Lindsey Gillgrass, Christine Etherington, Ian Clifton, Daniel G. Peckham

    Pseudo-Bartter syndrome (PBS) is characterised by hypokalaemic, hyponatraemic and hypochloraemic metabolic alkalosis in the absence of renal tubules pathology; it is a well-recognised complication of cystic fibrosis (CF), in the context of dehydration and acute illness [1–7].


  • Open Access

    Nasal high-flow therapy as an adjunct to exercise in patients with cystic fibrosis: A pilot feasibility trial

    by Giulia Spoletini, Ruth Watson, Wang Yng Lim, Kim Pollard, Christine Etherington, Ian J Clifton, Daniel G Peckham